Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29998843 | 1.00 | NR1H2 (0.74) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL545052 | 0.98 | NR1H2 (0.76) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4933173 | 0.95 | NR1H2 (0.76) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29175928 | 0.88 | NR1H2 (0.74) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL24566522 | 0.87 | NR1H2 (0.73) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15687976 | 0.86 | NR1H2 (0.90) | NR1H2ACHEALDH1A1KDM4EPOLB | |
| SCHEMBL29959115 | 0.86 | NR1H2 (0.90) | NR1H2ACHEALDH1A1KDM4EPOLB | |
| SCHEMBL24565655 | 0.86 | NR1H2 (0.64) | NR1H2ACHEALDH1A1KDM4EPOLB | |
| SCHEMBL15598307 | 0.85 | NR1H2 (0.74) | NR1H2ACHEALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL30900087 | 0.85 | NR1H2 (0.70) | NR1H2ACHEALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-3740484-B1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
| WO-2022008383-A1 | ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-13 | — | — | WO | disclosed |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-03-11 | — | — | US | disclosed |
| EP-2917214-B1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-28 | — | — | EP | disclosed |
| CN-104870446-B | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-108047219-A | Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor | 内尔维阿诺医学科学有限公司 | 2018-05-18 | — | — | CN | disclosed |
| CN-104870446-A | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2015-08-26 | — | — | CN | disclosed |
| WO-2014072220-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-05-15 | — | — | WO | disclosed |
| CN-1656073-B | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1511730-B1 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| CN-1656073-A | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | NR1H2 3397/4885ACHE 3683/4885ALDH1A1 4073/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | NR1H2 2865/4885ACHE 2252/4885ALDH1A1 3040/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | NR1H2 3397/4885ACHE 3683/4885ALDH1A1 4073/4885 |
| US-20210070746-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | NR1H2 3397/4885ACHE 3683/4885ALDH1A1 4073/4885 |
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | NR1H2 2147/4885ACHE 4583/4885ALDH1A1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.